NGM621

BIOLOGICAL3 trials

Sponsors

NGM Biopharmaceuticals, Inc

Conditions

Geographic AtrophySARS-CoV-2 Infection

Phase 1

Study of NGM621 in Participants With Geographic Atrophy

CompletedNCT04014777

NGM Biopharmaceuticals, IncGeographic Atrophy

Start: 2019-07-26End: 2020-05-27Updated: 2020-10-01

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

TerminatedNCT04582318

NGM Biopharmaceuticals, IncSARS-CoV-2 Infection

Start: 2020-11-09End: 2021-03-11Updated: 2022-02-25

Phase 2

A Study of NGM621 in Participants With Geographic Atrophy

CompletedNCT04465955

NGM Biopharmaceuticals, IncGeographic Atrophy

Start: 2020-07-22End: 2022-08-16Updated: 2025-07-01